Bempedoic Acid
Cardiovascular Risk Reduction (in statin-intolerant patients)
Key Facts
Indication
Cardiovascular Risk Reduction (in statin-intolerant patients)
Phase
Phase 3
Status
Outcomes Trial Completed
Company
About Esperion Therapeutics
Esperion Therapeutics is dedicated to improving cardiovascular health by providing convenient, oral therapies that lower LDL-cholesterol (LDL-C) for patients who cannot achieve their treatment goals with statins alone. The company achieved a major milestone with the U.S. FDA approval and commercial launch of NEXLETOL and NEXLIZET in 2020, supported by a robust outcomes trial (CLEAR Outcomes) demonstrating cardiovascular risk reduction. Its strategy focuses on expanding global market access, driving commercial adoption, and leveraging its bempedoic acid platform to potentially address other cardiometabolic conditions.
View full company profile